Guided Therapeutics (GTHP) Receivables (2016 - 2025)
Historic Receivables for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $6000.0.
- Guided Therapeutics' Receivables rose 20000.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6000.0, marking a year-over-year increase of 20000.0%. This contributed to the annual value of $3000.0 for FY2024, which is 5968.83% down from last year.
- Guided Therapeutics' Receivables amounted to $6000.0 in Q3 2025, which was up 20000.0% from $8000.0 recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Receivables registered a high of $165.1 million during Q1 2022, and its lowest value of $2000.0 during Q3 2024.
- Moreover, its 5-year median value for Receivables was $8000.0 (2025), whereas its average is $16.7 million.
- As far as peak fluctuations go, Guided Therapeutics' Receivables surged by 13095555.56% in 2022, and later tumbled by 9996.65% in 2023.
- Guided Therapeutics' Receivables (Quarter) stood at $171153.0 in 2021, then fell by 23.47% to $130984.0 in 2022, then tumbled by 94.32% to $7442.0 in 2023, then plummeted by 59.69% to $3000.0 in 2024, then surged by 100.0% to $6000.0 in 2025.
- Its Receivables stands at $6000.0 for Q3 2025, versus $8000.0 for Q2 2025 and $2000.0 for Q1 2025.